From single target to multitarget/network therapeutics in Alzheimer's therapy

Pharmaceuticals

Volumn 7, Issue 2, 2014, Pages 113-135

  Zheng, Hailin ^a   Fridkin, Mati ^b   Youdim, Moussa ^c  

^a Intra Cellular Therapies Inc   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c Abital Pharma Pipeline Ltd   (Israel)

Author keywords

AChE MAO A B inhibitor; Chelator; Ginkgo biloba; M30; M30D; Memantine; Nitromemantine; NMDA antagonist

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; ALPHA TOCOPHEROL; ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; CLIOQUINOL; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR; LEVODOPA; M 30D; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITROMEMANTINE; PLACEBO; RASAGILINE; RIVASTIGMINE; SELEGILINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIOACCUMULATION; CELL CYCLE REGULATION; COGNITIVE DEFECT; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXCITOTOXICITY; HOMEOSTASIS; HUMAN; MENTAL DISEASE; MOLECULAR MECHANICS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SUBACUTE MYELOOPTIC NEUROPATHY; UNSPECIFIED SIDE EFFECT;

EID: 84893494195     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph7020113     Document Type: Review

References (99)

1. Medina-Franco, J.L.; Giulianotti, M.A.; Welmaker, G.S.; Houghten, R.A. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov. Today 2013, 18, 495-501.
2. Opar, A. Mixed results for disease-modification strategies for Alzheimer's disease. Nat. Rev. Drug Discov. 2008, 7, 717-718.
3. Barabasi, A.L.; Gulbahce, N.; Loscalzo, J. Network medicine: A network-based approach to human disease. Nat. Rev. Genet. 2011, 12, 56-68.
4. Kitano, H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 2007, 6, 202-210.
5. Darreh-Shori, T.; Soininen, H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: A review of recent clinical studies. Curr. Alzheimer Res. 2010, 7, 67-73.
6. Ooi, S.L.; Pan, X.; Peyser, B.D.; Ye, P.; Meluh, P.B.; Yuan, D.S.; Irizarry, R.A.; Bader, J.S.; Spencer, F.A.; Boeke, J.D. Global synthetic-lethality analysis and yeast functional profiling. Trends Genet. 2006, 22, 56-63.
7. Hartman, J.L.; Garvik, B.; Hartwell, L. Principles for the buffering of genetic variation. Science 2001, 291, 1001-1004.
8. Britton, R.A.; Grossman, A.D. Synthetic lethal phenotypes caused by mutations affecting chromosome partitioning in Bacillus subtilis. J. Bacteriol. 1999, 181, 5860-5864.
9. Li, F.; Zhao, C.; Wang, L. Molecular-targeted agents combination therapy for cancer: Developments and potentials. Int. J. Cancer 2014, 134, 1257-1269.
10. Chow, V.W.; Savonenko, A.V.; Melnikova, T.; Kim, H.; Price, D.L.; Li, T.; Wong, P.C. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci. Transl. Med. 2010, 2, 13ra1.
11. Lehár, J.; Krueger, A.S.; Avery, W.; Heilbut, A.M.; Johansen, L.M.; Price, E.R.; Rickles, R.J.; Short, G.F.; Staunton, J.E.; Jin, X.; et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27, 659-666.
12. Couratier, P.; Lesort, M.; Sindou, P.; Esclaire, F.; Yardin, C.; Hugon, J. Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol. Chem. Neuropathol. 1996, 27, 259-273.
13. Esclaire, F.; Lesort, M.; Blanchard, C.; Hugon, J. Glutamate toxicity enhances tau gene expression in neuronal cultures. J. Neurosci. Res. 1997, 49, 309-318.
14. Li, S.; Hong, S.; Shepardson, N.E.; Walsh, D.M.; Shankar, G.M.; Selkoe, D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62, 788-801.
15. Alberdi, E.; Sanchez-Gomez, M.V.; Cavaliere, F.; Perez-Samartin, A.; Zugaza, J.L.; Trullas, R.; Domercq, M.; Matute, C. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010, 47, 264-272.
16. Mattson, M.P.; Cheng, B.; Davis, D.; Bryant, K.; Lieberburg, I.; Rydel, R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 1992, 12, 376-389.
17. Kabogo, D.; Rauw, G.; Amritraj, A.; Baker, G.; Kar, S. β-amyloid-related peptides potentiate K+-evoked glutamate release from adult rat hippocampal slices. Neurobiol. Aging 2010, 31, 1164-1172.
18. Lipton, S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat. Rev. Drug Discov. 2006, 5, 160-170.
19. Doody, R.S.; Tariot, P.N.; Pfeiffer, E.; Olin, J.T.; Graham, S.M. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2007, 3, 7-17.
20. Wong, E.H.; Kemp, J.A.; Priestley, T.; Knight, A.R.; Woodruff, G.N.; Iversen, L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. USA 1986, 83, 7104-7108.
21. Parsons, C.G.; Danysz, W.; Bartmann, A.; Spielmanns, P.; Frankiewicz, T.; Hesselink, M.; Eilbacher, B.; Quack, G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: In vitro and in vivo characterization. Neuropharmacology 1999, 38, 85-108.
22. Johnson, J.W.; Kotermanski, S.E. Mechanism of action of memantine. Curr. Opin. Pharmacol. 2006, 6, 61-67.
23. Maskell, P.D.; Speder, P.; Newberry, N.R.; Bermudez, I. Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br. J. Pharmacol. 2003, 140, 1313-1319.
24. Aracava, Y.; Pereira, E.F.; Maelicke, A.; Albuquerque, E.X. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 2005, 312, 1195-1205.
25. Rammes, G.; Rupprecht, R.; Ferrari, U.; Zieglgansberger, W.; Parsons, C.G. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci. Lett. 2001, 306, 81-84.
26. Seeman, P.; Caruso, C.; Lasaga, M. Memantine agonist action at dopamine D2High receptors. Synapse 2008, 62, 149-153.
27. Bickford-Wimer, P.; Kim, M.; Boyajian, C.; Cooper, D.M.; Freedman, R. Effects of pertussis toxin on caudate neuron electrophysiology: Studies with dopamine D1 and D2 agonists. Brain Res. 1990, 533, 263-267.
28. George, S.R.; Watanabe, M.; Di Paolo, T.; Falardeau, P.; Labrie, F.; Seeman, P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985, 117, 690-697.
29. Tremblay, R.; Chakravarthy, B.; Hewitt, K.; Tauskela, J.; Morley, P.; Atkinson, T.; Durkin, J.P. Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals. J. Neurosci. 2000, 20, 7183-7192.
30. Hu, M.; Schurdak, M.E.; Puttfarcken, P.S.; El Kouhen, R.; Gopalakrishnan, M.; Li, J. High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: Neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. Brain Res. 2007, 1151, 227-235.
31. Miguel-Hidalgo, J.J.; Alvarez, X.A.; Cacabelos, R.; Quack, G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. 2002, 958, 210-221.
32. Minkeviciene, R.; Rheims, S.; Dobszay, M.B.; Zilberter, M.; Hartikainen, J.; Fulop, L.; Penke, B.; Zilberter, Y.; Harkany, T.; Pitkanen, A.; et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci. 2009, 29, 3453-3462.
33. Dong, H.; Yuede, C.M.; Coughlan, C.; Lewis, B.; Csernansky, J.G. Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology 2008, 33, 3226-3236.
34. Unger, C.; Svedberg, M.M.; Yu, W.F.; Hedberg, M.M.; Nordberg, A. Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice. J. Pharmacol. Exp. Ther. 2006, 317, 30-36.
35. Song, M.S.; Rauw, G.; Baker, G.B.; Kar, S. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur. J. Neurosci. 2008, 28, 1989-2002.
36. Thornton, C.; Bright, N.J.; Sastre, M.; Muckett, P.J.; Carling, D. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem. J. 2011, 434, 503-512.
37. Li, L.; Sengupta, A.; Haque, N.; Grundke-Iqbal, I.; Iqbal, K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004, 566, 261-269.
38. Degerman Gunnarsson, M.; Kilander, L.; Basun, H.; Lannfelt, L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2007, 24, 247-252.
39. Willard, L.B.; Hauss-Wegrzyniak, B.; Danysz, W.; Wenk, G.L. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. 2000, 134, 58-65.
40. Rosi, S.; Vazdarjanova, A.; Ramirez-Amaya, V.; Worley, P.F.; Barnes, C.A.; Wenk, G.L. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 2006, 142, 1303-1315.
41. Wu, H.M.; Tzeng, N.S.; Qian, L.; Wei, S.J.; Hu, X.; Chen, S.H.; Rawls, S.M.; Flood, P.; Hong, J.S.; Lu, R.B. Novel neuroprotective mechanisms of memantine: Increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009, 34, 2344-2357.
42. Liu, W.; Xu, Z.; Deng, Y.; Xu, B.; Wei, Y.; Yang, T. Protective effects of memantine against methylmercury-induced glutamate dyshomeostasis and oxidative stress in rat cerebral cortex. Neurotox. Res. 2013, 24, 320-337.
43. Benilova, I.; Karran, E.; de Strooper, B. The toxic Abeta oligomer and Alzheimer's disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349-357.
44. Figueiredo, C.P.; Clarke, J.R.; Ledo, J.H.; Ribeiro, F.C.; Costa, C.V.; Melo, H.M.; Mota-Sales, A.P.; Saraiva, L.M.; Klein, W.L.; Sebollela, A.; et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J. Neurosci. 2013, 33, 9626-9634.
45. Weiner, M.W.; Sadowsky, C.; Saxton, J.; Hofbauer, R.K.; Graham, S.M.; Yu, S.Y.; Li, S.; Hsu, H.A.; Suhy, J.; Fridman, M.; et al. Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. Alzheimers Dement. 2011, 7, 425-435.
46. Wilkinson, D.; Andersen, H.F. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2007, 24, 138-145.
47. Lipton, S.A.; Choi, Y.B.; Pan, Z.H.; Lei, S.Z.; Chen, H.S.; Sucher, N.J.; Loscalzo, J.; Singel, D.J.; Stamler, J.S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993, 364, 626-632.
48. Choi, Y.B.; Tenneti, L.; Le, D.A.; Ortiz, J.; Bai, G.; Chen, H.S.; Lipton, S.A. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci. 2000, 3, 15-21.
49. Wang, Y.; Eu, J.; Washburn, M.; Gong, T.; Chen, H.S.; James, W.L.; Lipton, S.A.; Stamler, J.S.; Went, G.T.; Porter, S. The pharmacology of aminoadamantane nitrates. Curr. Alzheimer Res. 2006, 3, 201-204.
50. Dawson, V.L.; Dawson, T.M.; London, E.D.; Bredt, D.S.; Snyder, S.H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 1991, 88, 6368-6371.
51. Talantova, M.; Sanz-Blasco, S.; Zhang, X.; Xia, P.; Akhtar, M.W.; Okamoto, S.; Dziewczapolski, G.; Nakamura, T.; Cao, G.; Pratt, A.E.; et al. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. USA 2013, 110, E2518-E2527.
52. Hardingham, G.E.; Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11, 682-696.
53. Zheng, H.; Fridkin, M.; Youdim, M.B. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer's therapy. Curr. Drug Targets 2012, 13, 1089-1106.
54. Atri, A.; Shaughnessy, L.W.; Locascio, J.J.; Growdon, J.H. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008, 22, 209-221.
55. Atri, A.; Molinuevo, J.L.; Lemming, O.; Wirth, Y.; Pulte, I.; Wilkinson, D. Memantine in patients with Alzheimer's disease receiving donepezil: New analyses of efficacy and safety for combination therapy. Alzheimers Res. Ther. 2013, 5, 6.
56. Simoni, E.; Daniele, S.; Bottegoni, G.; Pizzirani, D.; Trincavelli, M.L.; Goldoni, L.; Tarozzo, G.; Reggiani, A.; Martini, C.; Piomelli, D.; et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J. Med. Chem. 2012, 55, 9708-9721.
57. Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tammer, A.; et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch. Neurol. 2003, 60, 1685-1691.
58. Wikipedia, Selegiline. Available online: http://en.wikipedia.org/wiki/Selegiline (accessed on 15 September 2013).
59. Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C.W.; Pfeiffer, E.; et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Engl. J. Med. 1997, 336, 1216-1222.
60. Birks, J.; Flicker, L. Selegiline for Alzheimer's disease. Cochrane Database Syst. Rev. 2003, 1, CD000442.
61. Sung, S.; Yao, Y.; Uryu, K.; Yang, H.; Lee, V.M.; Trojanowski, J.Q.; Pratico, D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004, 18, 323-325.
62. Petersen, R.C.; Bennett, D. Mild cognitive impairment: Is it Alzheimer's disease or not? J. Alzheimers Dis. 2005, 7, 241-245.
63. Lee, H.P.; Zhu, X.; Casadesus, G.; Castellani, R.J.; Nunomura, A.; Smith, M.A.; Lee, H.G.; Perry, G. Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev. Neurother. 2010, 10, 1201-1208.
64. Olanow, C.W.; Rascol, O.; Hauser, R.; Feigin, P.D.; Jankovic, J.; Lang, A.; Langston, W.; Melamed, E.; Poewe, W.; Stocchi, F.; et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361, 1268-1278.
65. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 2010, 92, 330-344.
66. Faux, N.G.; Ritchie, C.W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; et al. PBT2 rapidly improves cognition in Alzheimer's Disease: Additional phase II analyses. J. Alzheimers Dis. 2010, 20, 509-516.
67. Ritchie, C.W.; Bush, A.I.; Masters, C.L. Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin. Investig. Drugs 2004, 13, 1585-1592.
68. Zheng, H.; Gal, S.; Weiner, L.M.; Bar-Am, O.; Warshawsky, A.; Fridkin, M.; Youdim, M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 2005, 95, 68-78.
69. Gal, S.; Zheng, H.; Fridkin, M.; Youdim, M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 2005, 95, 79-88.
70. Gal, S.; Abassi, Z.A.; Youdim, M.B. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox. Res. 2010, 18, 143-150.
71. Zheng, H.; Weiner, L.M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z.I.; Warshawsky, A.; Youdim, M.B.; Fridkin, M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 2005, 13, 773-783.
72. Kupershmidt, L.; Amit, T.; Bar-Am, O.; Youdim, M.B.; Weinreb, O. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech. Ageing Dev. 2012, 133, 267-274.
73. Kupershmidt, L.; Weinreb, O.; Amit, T.; Mandel, S.; Carri, M.T.; Youdim, M.B. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2009, 23, 3766-3779.
74. Kupershmidt, L.; Amit, T.; Bar-Am, O.; Weinreb, O.; Youdim, M.B. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice. Mol. Neurobiol. 2012, 46, 217-220.
75. Kupershmidt, L.; Amit, T.; Bar-Am, O.; Youdim, M.B.; Weinreb, O. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid. Redox Signal. 2012, 17, 860-877.
76. Avramovich-Tirosh, Y.; Bar-Am, O.; Amit, T.; Youdim, M.B.; Weinreb, O. Up-regulation of hypoxia-inducible factor (HIF) 1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr. Alzheimer Res. 2010, 7, 300-306.
77. Kupershmidt, L.; Weinreb, O.; Amit, T.; Mandel, S.; Bar-Am, O.; Youdim, M.B. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 2011, 189, 345-358.
78. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem. Pharmacol. 2003, 65, 407-416.
79. Mancini, F.; Naldi, M.; Cavrini, V.; Andrisano, V. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal. Bioanal. Chem. 2007, 388, 1175-1183.
80. Meunier, J.; Ieni, J.; Maurice, T. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J. Pharmacol. Exp. Ther. 2006, 317, 1307-1319.
81. Kimura, M.; Akasofu, S.; Ogura, H.; Sawada, K. Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. Brain Res. 2005, 1047, 72-84.
82. Kimura, M.; Komatsu, H.; Ogura, H.; Sawada, K. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neurosci. Lett. 2005, 391, 17-21.
83. Meunier, J.; Ieni, J.; Maurice, T. The anti-amnesic and neuroprotective effects of donepezil against amyloid β25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br. J. Pharmacol. 2006, 149, 998-1012.
84. Pepeu, G.; Giovannini, M.G. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res. 2009, 6, 86-96.
85. Pohanka, M. Acetylcholinesterase inhibitors: A patent review (2008-present). Expert Opin. Ther. Pat. 2012, 22, 871-886.
86. Zheng, H.; Youdim, M.B.; Fridkin, M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem. Biol. 2010, 5, 603-610.
87. Mahadevan, S.; Park, Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses. J. Food Sci. 2008, 73, R14-R19.
88. Fehske, C.J.; Leuner, K.; Muller, W.E. Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol. Res. 2009, 60, 68-73.
89. Koch, E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: Considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 2005, 12, 10-16.
90. Koltermann, A.; Hartkorn, A.; Koch, E.; Furst, R.; Vollmar, A.M.; Zahler, S. Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell. Mol. Life Sci. 2007, 64, 1715-1722.
91. Winter, J.C.; Timineri, D. The discriminative stimulus properties of EGb 761, an extract of Ginkgo biloba. Pharmacol. Biochem. Behav. 1999, 62, 543-547.
92. Wu, Y.; Wu, Z.; Butko, P.; Christen, Y.; Lambert, M.P.; Klein, W.L.; Link, C.D.; Luo, Y. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 2006, 26, 13102-13113.
93. Bastianetto, S.; Ramassamy, C.; Dore, S.; Christen, Y.; Poirier, J.; Quirion, R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur. J. Neurosci. 2000, 12, 1882-1890.
94. Kampkotter, A.; Pielarski, T.; Rohrig, R.; Timpel, C.; Chovolou, Y.; Watjen, W.; Kahl, R. The Ginkgo biloba extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in Caenorhabditis elegans. Pharmacol. Res. 2007, 55, 139-147.
95. Mazza, M.; Capuano, A.; Bria, P.; Mazza, S. Ginkgo biloba and donepezil: A comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur. J. Neurol. 2006, 13, 981-985.
96. McCarney, R.; Fisher, P.; Iliffe, S.; van Haselen, R.; Griffin, M.; van der Meulen, J.; Warner, J. Ginkgo biloba for mild to moderate dementia in a community setting: A pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int. J. Geriatr. Psychiatry 2008, 23, 1222-1230.
97. Snitz, B.E.; O'Meara, E.S.; Carlson, M.C.; Arnold, A.M.; Ives, D.G.; Rapp, S.R.; Saxton, J.; Lopez, O.L.; Dunn, L.O.; Sink, K.M.; et al. Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA 2009, 302, 2663-2670.
98. Ihl, R.; Bachinskaya, N.; Korczyn, A.D.; Vakhapova, V.; Tribanek, M.; Hoerr, R.; Napryeyenko, O. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: A randomized controlled trial. Int. J. Geriatr. Psychiatry 2011, 26, 1186-1194.
99. Brondino, N.; de Silvestri, A.; Re, S.; Lanati, N.; Thiemann, P.; Verna, A.; Emanuele, E.; Politi, P. A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine. Evid. Based Complement. Alternat. Med. 2013, 2013, 915691.